



EDAP Launches Enhanced Web Site

LYON, France, July 31, 2008 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, announced today the launch of an enhanced Web site containing expanded and user-friendly features based on best practices within the healthcare industry. Visitors can access the new site at www.edap-tms.com.

The upgraded site provides visitors with easier access to the Company's full range of HIFU and lithotripsy products and services. The site also offers new self-service features and improved navigation, including an event-centric stock chart, a download library and contact information for specific inquiries.

Marc Oczachowski, EDAP's Chief Executive Officer stated, "This enhanced Web site accomplishes our goal to create a single, worldwide online resource that centralizes our communication strategies dedicated to our customers, patients, investors and partners. In addition to assisting visitors in obtaining data on our innovative and minimally invasive solutions, it also refers viewers to EDAP's comprehensive educational web sites: www.hifu-planet.com, www.pcaresearch.com and Urotoday's informative site www.urotoday.com/HIFU."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit <http://www.edap-tms.com>, <http://www.hifu-planet.com> and <http://www.pcaresearch.com> or <http://www.urotoday.com/HIFU>.

Contact:

Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com

Investors:

R.J. Pellegrino
The Ruth Group
646-536-7009
rpellegrino@theruthgroup.com